DJIA 15,303.10 8.60 0.06%
NASDAQ 3,459.14 -0.28 -0.01%
S&P 500 1,649.60 -0.91 -0.06%

Sarepta Therapeutics

NASDAQ: SRPT

+ Add to Portfolio

company name or ticker

Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In

4/11/2013 by Seeking Alpha

Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agre

Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy
4/11/2013 by Benzinga

Whoa! What Just Happened to My Stock?

These stocks bounced higher yesterday, but are they about to make a return trip to Earth?
4/10/2013 by DailyFinance

Hey Sarepta Investors: Glaxo's Drisapersen Data Revealed Early

4/9/2013 by TheStreet

UPDATE: Canaccord Genuity Initiates Sarepta Therapeutics with Buy on Etepliersen Uptake Potential

4/9/2013 by Benzinga

2 Biotechs With 40%+ Moves Coming

4/8/2013 by Seeking Alpha

Sarepta-Glaxo Duchenne's Rivalry Heats Up This Week

4/8/2013 by TheStreet

Sarepta's Eteplirsen Walks Closer to Success

Duchenne muscular dystrophy patients taking eteplirsen keep walking. And so do Sarepta's shares.
4/5/2013 by DailyFinance

5 Stocks Rising on Unusual Volume

4/5/2013 by TheStreet

Benzinga's Volume Movers

4/5/2013 by Benzinga
See More Articles...